Calculator helps identify patients with esophageal cancer who will benefit from neoadjuvant chemoradiation

By News Release
0  Votes

Cancer of the esophagus, the hollow tube connecting the oral cavity to the stomach, is more often diagnosed in men than in women and is usually treated surgically. Roswell Park Cancer Institute researchers have created a novel calculator that more readily identifies patients who may benefit from therapy that reduces the extent of the disease prior to surgery. The study has been published online ahead of print by the Journal of the American College of Surgeons.

Using the National Cancer Data Base, the Roswell Park team evaluated clinical data for 8,974 patients diagnosed with early stage esophageal cancer. The database records information for as many as 70% of the nation’s cancer cases through participating hospitals. The researchers evaluated characteristics such as patients’ comorbidity score, tumor grade and neoadjuvant chemoradiation status (whether they had chemotherapy and/or radiation prior to surgery). Only preoperative data were used to develop the calculator. The scientists found that patients who benefit more from neoadjuvant chemoradiation included those whose tumors had metastasized to nearby lymph nodes, older patients and those with more aggressive cancers, such as tumors of higher grade and greater depth of invasion. These findings indicate that the calculator would assist physicians and patients with treatment decision-making.

“The use of calculators to estimate outcomes is becoming increasingly common, and is being applied to real-time clinical situations to aid in treatment decision-making and individualizing therapy,” says the lead author of the study, Emmanuel Gabriel, MD, PhD, of the Department of Surgical Oncology at Roswell Park.

“Our effort is a good example of how you can use large national databases to create calculators to guide and improve preoperative decision-making. Such tools can help us, for example, to avoid the toxic side effects of upfront chemoradiotherapy in a subset of patients. However, our calculator should be validated prospectively before firm conclusions can be drawn about its value in treatment selection,” notes the senior author of the study, Moshim Kukar, MD, assistant professor of Surgery in the Department of Surgical Oncology at Roswell Park.

This research was supported, in part, by a grant from the National Cancer Institute (award no. P30CA016056). The study, “Novel Calculator to Estimate Overall Survival Benefit from Neoadjuvant Chemoradiation in Patients with Esophageal Adenocarcinoma,” is available at

Back To Top

Calculator helps identify patients with esophageal cancer who will benefit from neoadjuvant chemoradiation.  Appl Rad Oncol. 

By News Release| March 08, 2017

About the Author

News Release

News Release


Copyright © Anderson Publishing, Ltd